drugset / Trial / NCT00242554

Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases

NCT00242554

Phase 4 Completed 150 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the effects of i.v. zoledronic acid 4 mg with respect to safety and tolerability

Timeline

Start
2002-10
Primary completion
2007-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 4 mg Intravenous

Indications